Biotechnology

A new alliance aims to replace painful biopsies with high-res biology, mapping organ rejection at the cellular level to usher in a new era of personalized care.

With positive Phase 2 results for its antibody AP-101, AL-S Pharma targets a key protein in both genetic and sporadic forms of ALS, offering new hope.

New data from a major Swedish study reveals SAGA Diagnostics' Pathlight test can predict colorectal cancer recurrence with remarkable accuracy, changing the game.

A new multi-target deal combines cutting-edge platforms to create next-gen cancer drugs, aiming to improve precision and patient outcomes.

A new alliance pairs Relation's 'Lab-in-the-Loop' AI with Deerfield's investment might, aiming to fast-track novel drugs for intractable diseases.

A first-in-class antibody shows a strong safety profile, de-risking development and offering a new, targeted approach for severe autoimmune diseases.

With its first drug approved and a deep pipeline, all eyes are on Nuvation Bio's CEO David Hung at the upcoming J.P. Morgan Healthcare Conference.

LifeVantage heads to the ICR Conference to woo investors. Can its cellular health science overcome market headwinds and a volatile direct selling landscape?

A landmark trial reveals a new drug combination from BeOne Medicines extends life significantly in advanced stomach cancer, poised to become the new standard.

With its lead asset TEC-001 targeting tough liver cancers, Teclison's presence at the ASCO GI Symposium puts its innovative approach in the spotlight.

With a new CEO who has three FDA-approved drugs to his name, Catalio-backed Rhapsogen is poised to redefine autoimmune disease treatment. Here's why.

A promising antiviral combination for Long COVID gets a major boost, accelerating its path to a pivotal clinical trial led by top researchers.

A groundbreaking Duke trial combines a novel device to lure cancer cells with targeted immunotherapy, offering real-time tracking and new hope for patients.

With its rare disease drug JURVIGO® in late-stage trials, Mezzion appoints a veteran leader to navigate the path to approval and commercialization.

A new AI-powered simulation engine promises to replace strategic gut feelings with statistical certainty, helping companies navigate high-stakes decisions.

With enrollment complete for three major trials, MediciNova braces for a transformative year with crucial data expected for its ALS and metabolic disease candidates.

A new philanthropic fund, Lupus Ventures, aims to end treatment stagnation by investing directly in the most promising biotech innovations for lupus.

With its lead muscular dystrophy drug in late-stage trials, Edgewise Therapeutics heads to the JPM conference with high stakes for its pipeline and stock.

A new antibody-drug conjugate, DEM301, shows preclinical promise by targeting a unique protein to directly kill tumors and unleash the immune system.

With its first drug for a rare disease now on the market, Stealth BioTherapeutics bets its future on a deep pipeline targeting mitochondrial dysfunction.